Why did you prioritize translational medicine?

We have seen a deluge of new discoveries in the last few years on the molecular basis of disease. This is true for rare diseases, common diseases and neglected diseases, and allows us to feed new ideas into the therapeutic pipeline. That's the good news. But there is bad news too. Despite increasing investments by the private sector, there has been a downturn in the number of approved new molecular entities over the last few years. Also, drug development research remains very expensive and the failure rate is extremely high.

Login or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD